Patent Number: 7,820,635

Title: RNAi probes targeting cancer-related proteins

Abstract: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Inventors: Gleave; Martin (Vancouver, CA), Jansen; Burkhard (Vancouver, CA), Trougakos; Ioannis P (Athens, GR), Gonos; Efstathios (Athens, GR), Signaevsky; Maxim (Vancouver, CA), Beraldi; Eliana (Vancouver, CA)

Assignee: The University of British Columbia

International Classification: A61K 48/00 (20060101)

Expiration Date: 2018-10-26 0:00:00